The Korean Journal of Medicine

  • 제87권5호
  • /
  • Pages.530-536
  • /
  • 2014
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

진행성 노인 대장암에 대한 항암요법

Chemotherapy in Elderly Patients with Colorectal Cancer

  • 한혜숙 (충북대학교 의과대학 내과학교실)
  • Han, Hye Sook (Department of Internal Medicine, College of Medicine, Chungbuk National University)
  • 발행 : 2014.11.01
⟨ 이전 논문 다음 논문 ⟩

초록

Colorectal cancer (CRC) affects largely elderly populations. However, older patients with CRC are generally excluded from randomized clinical trials, and the healthy subjects who are recruited are not representative of the general elderly patient population. Nevertheless, recent data from clinical trials specifically targeting elderly patients and related subgroup analyses indicate that well-selected elderly patients can have a similar response to that of younger patients. Chronological age should not determine the candidacy for adjuvant or palliative chemotherapy in elderly patients with CRC. The appropriate management of healthy elderly patients would mean that they could receive aggressive chemotherapy in a similar regimen to that of younger patients, whereas the care of frail elderly patients and those with a short life expectancy should focus on palliation. The use of a comprehensive geriatric assessment could allow the use of safe and beneficial chemotherapy regimens in elderly patients with CRC.

키워드

참고문헌

  1. Statistic Korea [Internet]. Daejeon: Statistics Korea; 2014 [cited 2014 Jan 24]. Available from: http://kostat.go.kr
  2. Yancik R. Population aging and cancer: a cross-national concern. Cancer J 2005;11:437-441. https://doi.org/10.1097/00130404-200511000-00002
  3. National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2011 [Internet]. Bethesda (MD): National Cancer Institute, c2011 [cited 2013 Oct 20]. Available from: http://seer.cancer.gov/csr/1975_2011/.
  4. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Prediction of cancer incidence and mortality in Korea, 2014. Cancer Res Treat 2014;46:124-130. https://doi.org/10.4143/crt.2014.46.2.124
  5. Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014 Jul 28[Epub]. pii: JCO.2013.54.8347.
  6. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: Senior Adult Oncology [Internet]. Washington (PA): National Comprehensive Cancer Network, c2014 [cited 2014 Jan 11]. Available from: http://www.nccn.org/professionals/physician_gls.
  7. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704. https://doi.org/10.1056/NEJMoa043116
  8. Cassidy J, Twelves C, Van Cutsem E, et al; Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575. https://doi.org/10.1093/annonc/mdf089
  9. Andre T, Boni C, Mounedji-Boudiaf L, et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351. https://doi.org/10.1056/NEJMoa032709
  10. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:1465-1471. https://doi.org/10.1200/JCO.2010.33.6297
  11. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005;294:2703-2711. https://doi.org/10.1001/jama.294.21.2703
  12. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1097. https://doi.org/10.1056/NEJMoa010957
  13. Iwashyna TJ, Lamont EB. fectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002;20:3992-3998. https://doi.org/10.1200/JCO.2002.03.083
  14. McCleary NJ, Meyerhardt JA, Green E, et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013;31:2600-2606. https://doi.org/10.1200/JCO.2013.49.6638
  15. Sanoff HK, Carpenter WR, Stürmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012;30:2624-2634. https://doi.org/10.1200/JCO.2011.41.1140
  16. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523-3529. https://doi.org/10.1200/JCO.2007.15.4138
  17. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008;19:1720-1726. https://doi.org/10.1093/annonc/mdn370
  18. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer:updated results from the BICC-C study. J Clin Oncol 2008;26:689-690. https://doi.org/10.1200/JCO.2007.15.5390
  19. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004;15:1330-1338. https://doi.org/10.1093/annonc/mdh344
  20. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005;23:3104-3111. https://doi.org/10.1200/JCO.2005.06.035
  21. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008;26:1443-1451. https://doi.org/10.1200/JCO.2007.14.0509
  22. Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 2009;115:2617-2629. https://doi.org/10.1002/cncr.24305
  23. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-4091. https://doi.org/10.1200/JCO.2006.06.9039
  24. Seymour MT, Thompson LC, Wasan HS, et al; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011;377:1749-1759. https://doi.org/10.1016/S0140-6736(11)60399-1
  25. Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010;136: 737-743. https://doi.org/10.1007/s00432-009-0712-3
  26. Cunningham D, Lang I, Marcuello E, et al; AVEX study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14:1077-1085. https://doi.org/10.1016/S1470-2045(13)70154-2
  27. Douillard JY, Oliner KS, Siena S, et al. Panitumumab- FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-1034. https://doi.org/10.1056/NEJMoa1305275
  28. Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS. Expended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Ann Oncol 2014 Aug 12[Epub]. pii: mdu378.
  29. Sastre J, Gravalos C, Rivera F, et al. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 2012;17:339-345. https://doi.org/10.1634/theoncologist.2011-0406
  30. Folprecht G, Kohne C, Bokemeyer C, et al. Cetuximab and 1st line chemotherapy in elderly and younger patients with metastatic colorectal cancer (mCRC): a pooled analysis of the CRYSTAL and OPUS studies. Ann Oncol 2010;21 (Suppl. 8): abstract 597P